Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AnaptysBio, Inc.

Anaptys Announces Stock Repurchase Plan
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys Announces Participation in March Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB VNDA
Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys Announces Participation in November and December Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys Announces Participation in September Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB CNTA
Anaptys Named a BioSpace 2024 Best Places to Work Winner
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys Announces Participation in November Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update
From AnaptysBio, Inc.
Via GlobeNewswire
Tickers ANAB
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.